Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | IDH1 | O75874 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 4/20 | 0.34 |
| ▸ | KRAS | P01116 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14429455 | 0.83 | HTT (0.38) | — | |
| SCHEMBL1605184 | 0.83 | MAPKAPK2 (0.44) | IDH1 | |
| SCHEMBL1605772 | 0.83 | MAPKAPK2 (0.44) | IDH1 | |
| SCHEMBL1606506 | 0.82 | MAPT (0.45) | LMNAKMT2AL3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL5464521 | 0.80 | IDH1 (0.42) | IDH1SOS1KRASKMT2AHPGD | |
| SCHEMBL1606527 | 0.80 | IDH1 (0.42) | IDH1SOS1KRASKMT2AHPGD | |
| SCHEMBL1606605 | 0.80 | IDH1 (0.42) | IDH1SOS1KRASKMT2AHPGD | |
| SCHEMBL1605418 | 0.80 | TAAR1 (0.46) | IDH1LMNAKMT2AROCK2ROCK1 | |
| SCHEMBL1605556 | 0.80 | TAAR1 (0.46) | IDH1LMNAKMT2AROCK2ROCK1 | |
| SCHEMBL1606754 | 0.76 | P2RX7 (0.39) | LMNAROCK2L3MBTL1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541592-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 | AMGEN INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541592-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 | AMGEN INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20070197598-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197598-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007061661-A2 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197598-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | CA1 1467/4885CA2 2488/4885ACHE 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.